Aviron FluMist
Executive Summary
FDA does not accept June 30 PLA/ELA submission, stating that it requires additional information on manufacturing processes and facilities. Evans Medical will conduct bulk manufacturing and PCI will do secondary manufacturing of the influenza vaccine. Aviron said the additional information requested "is on-track and was already planned for submission in October." However, FDA may require another trial bridging the manufacturing process used for the Phase III trial to the process planned for marketing. Such a trial could delay the planned commercialization for the 1999-2000 flu season, the company said. Aviron has requested a meeting with FDA
You may also be interested in...
Medeva Fluvirin Production Returns To Market-Demand Level
Production of Medeva's influenza vaccine Fluvirin has returned to levels of market demand following improvements in the manufacturing process, the company said.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011